Aslani, Iris .
HRN: 24-25-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/13/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/13/2024
05/20/2024
IV
40
Q12
PCAP, T/C CNS Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueCentral Nervous System Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes